Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

September 7, 2023

Study Completion Date

September 7, 2023

Conditions
Primary Open-Angle Glaucoma (POAG)
Interventions
DRUG

Mexidol

Neuroretinoprotector

OTHER

Placebo

Placebo therapy

Trial Locations (7)

127473

"Federal State Budgetary Educational Institution of Higher Education Moscow State Medical and Dental Institute named after A.I. Evdokimov of the Ministry of Health of the RF", Moscow

127486

"Federal State Autonomous Institution Intersectoral Scientific and Technical Complex Eye Microsurgery named after Academician S.N. Fedorov of the Ministry of Health of the RF", Moscow

150030

"State Budgetary Institution of Healthcare of the Yaroslavl Region Clinical Hospital No. 2", Yaroslavl

197706

"Saint Petersburg State Budgetary Healthcare Institution State Hospital No. 40 of the Kurortny District", Saint Petersburg

410004

"Private healthcare institution Clinical hospital RZhD-Medicine of the city of Saratov", Saratov

610047

"Kirov Regional State Budgetary Healthcare Institution Kirov Clinical Ophthalmological Hospital", Kirov

644024

"Budgetary healthcare institution of the Omsk region V.P. Vyhodtsev Clinical Ophthalmological Hospital", Omsk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pharmasoft

INDUSTRY